KPV vs VIP
Both KPV and VIP are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | KPV | VIP |
|---|---|---|
| Evidence Grade | C+ | B |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | 200–500 mcg orally or topical (research only) | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 26 | 24 |
| Categories | anti-inflammatory, gut-health, skin | anti-inflammatory, neuroprotection |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.